Stifel analyst Laura Prendergast raised the firm’s price target on Nuvalent (NUVL) to $135 from $115 and keeps a Buy rating on the shares after the company presented topline pivotal data from the registration enabling Ph1/2 ALKove-1 study of neladalkib in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer. The firm considers these data and EAP enrollment commentary “highly encouraging,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $149 from $140 at Leerink
- Nuvalent’s Neladalkib: Promising ALK+ NSCLC Treatment with Strong Phase 2 Data and De-risked Approval Path
- Nuvalent’s Promising Future: Buy Rating Backed by ALKOVE-1 Study Success and Strategic Growth Plans
- Nuvalent price target raised to $155 from $130 at H.C. Wainwright
- Nuvalent Announces Positive Data for ALKOVE-1 Trial